Precision personalized medicine to address unresolved cases of hereditary cancer.

The IMPaCT_VUSCan project, led by the Bellvitge Biomedical Research Institute (IDIBELL), focuses on improving genetic testing for hereditary cancer diagnosis through biomedical research.

It specifically targets the identification and definitive classification of variants of unknown significance (VUS).

The project implements a comprehensive functional genomics strategy aimed at finding clinical applications for these VUS, thereby aiding in the resolution of more cases with potential cancer predisposition.

To achieve this, the scientific team will utilize artificial intelligence and multiomic techniques.

Additionally, IMPaCT_VUSCan will provide a validated protocol for genetic characterization of hereditary cancer to facilitate clinical decision-making nationwide, with the participation of other centers in the project, including the Research Institute of the Hospital de Sant Pau de Barcelona (IIB) and IDISBA in Palma.